- Report
- February 2023
- 48 Pages
Global
From €3485EUR$3,995USD£3,035GBP
- Report
- February 2026
Global
From €450EUR$553USD£406GBP
- Newsletter
- February 2026
- 2 Pages
Global
From €114EUR$131USD£100GBP
- Report
- October 2023
- 85 Pages
United States
From €4231EUR$4,850USD£3,684GBP
- Report
- July 2023
- 200 Pages
Global
From €3925EUR$4,500USD£3,419GBP
- Report
- July 2023
- 218 Pages
Global
From €3925EUR$4,500USD£3,419GBP
- Report
- July 2022
- 40 Pages
China
From €2791EUR$3,200USD£2,431GBP
- Report
- August 2019
- 42 Pages
Global
€2613EUR$2,995USD£2,275GBP
- Report
- August 2018
- 21 Pages
Global
From €8723EUR$10,000USD£7,597GBP
- Report
- April 2018
United States
From €6974EUR$7,995USD£6,074GBP
- Report
- January 2024
- 85 Pages
Global
From €3500EUR$4,298USD£3,155GBP
- Report
- September 2025
- 96 Pages
Global
From €3500EUR$4,298USD£3,155GBP
- Report
- September 2024
- 101 Pages
Global
From €3500EUR$4,298USD£3,155GBP
- Report
- October 2023
- 94 Pages
Global
From €3500EUR$4,298USD£3,155GBP
- Report
- August 2023
- 107 Pages
Global
From €3500EUR$4,298USD£3,155GBP
- Report
- January 2025
- 132 Pages
Global
From €829EUR$950USD£722GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more